VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NBTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NBTXNanobiotix S.A.
$26.90$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNBTXFinancials

Nanobiotix S.A. (NBTX) Income Statement

15Y historyFree accessUpdated daily

Revenue has been highly volatile and partner-dependent, with quarterly results ranging from -$16.5M to $32.9M, while the 100% gross margin reflects a licensing profile and operating margins remained negative at -3.2% in 2026Q2 against a net loss of $34.7M.

Income StatementBalance SheetCash FlowRatios

NBTX Income Statement

Annual statement

NBTX Income Statement

Nanobiotix S.A. (NBTX) annual income statement — 15-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Sales/Revenue18.71M29.64M-7.19M36.21M4.78M2.65M2.33M2.54M3.48M3.72M5.42M4.02M2.77M1.6M970.61K1.36M
Revenue Growth %-512.28%-119.86%658.12%80.43%13.85%-8.5%-26.96%-6.53%-31.35%35.03%44.91%73.67%64.38%-28.65%-
Cost of Goods Sold0000000000000000
COGS % of Revenue----------------
Gross Profit18.71M29.64M-7.19M36.21M4.78M2.65M2.33M2.54M3.48M3.72M5.42M4.02M2.77M1.6M970.61K1.36M
Gross Margin %-100%100%100%100%100%100%100%100%100%100%100%100%100%100%100%
Gross Profit Growth %-512.28%-119.86%658.12%80.43%13.85%-8.5%-26.96%-6.53%-31.35%35.03%44.91%73.67%64.38%-28.65%-
Operating Expenses92.2M40.46M61.2M62.99M51.48M55.23M38.75M49.32M33.55M28.99M27.28M21.16M12.39M9.77M6.15M5.23M
OpEx % of Revenue-136.49%-851.21%173.96%1077.85%2086.36%1666.8%1940.97%964.24%778.86%503.1%526.92%447.18%612.67%633.18%384.27%
Selling, General & Admin40.58M20.22M20.53M22.05M17.86M19.43M14.61M18.91M12.65M11.26M10.36M7.25M4.31M3.75M1.81M1.3M
SG&A % of Revenue-68.22%-285.49%60.9%373.89%734.19%628.43%744.16%363.7%302.39%191.11%180.69%155.73%234.99%186.63%95.56%
Research & Development53.49M23.11M40.54M38.4M32.64M30.38M24.33M30.41M20.89M17.73M16.92M13.9M8.08M6.03M4.31M5.21M
R&D % of Revenue-77.98%-563.85%106.04%683.33%1147.64%1046.45%1196.81%600.55%476.44%312%346.23%291.46%377.67%444.26%383.2%
Other Operating Expenses5.3K-2.88M134K2.54M985K5.41M-188K001K000000
Operating Income-73.48M-10.82M-68.39M-26.78M-46.7M-52.58M-36.43M-46.78M-30.07M-25.27M-21.85M-17.14M-9.62M-8.18M-5.15M-5.23M
Operating Margin %--36.49%951.21%-73.96%-977.85%-1986.36%-1566.8%-1840.97%-864.24%-678.86%-403.1%-426.92%-347.18%-512.67%-530.89%-384.27%
Operating Income Growth %-84.18%-155.39%42.66%11.18%-44.34%22.13%-55.58%-19%-15.61%-27.49%-78.19%-17.61%-58.74%1.42%-
EBITDA-70.24M-9.32M-66.77M-25.27M-45.2M-51.02M-34.67M-45.01M-29.45M-24.78M-21.37M-16.69M-9.31M-7.95M-5.01M-5.03M
EBITDA Margin %--31.45%928.66%-69.78%-946.44%-1927.43%-1491.35%-1771.43%-846.45%-665.72%-394.2%-415.56%-336.08%-498%-515.79%-369.74%
EBITDA Growth %-86.04%-164.27%44.1%11.4%-47.14%22.97%-52.85%-18.85%-15.94%-28.09%-79.18%-17.2%-58.71%0.46%-
D&A (Non-Cash Add-back)3.24M1.5M1.62M1.51M1.5M1.56M1.75M1.77M619K489K482.79K456.08K307.56K233.93K146.53K197.62K
EBIT-78.39M-13.56M-68.26M-24.24M-45.72M-47.16M-36.62M-46.78M-30.07M-25.27M-21.85M-17.14M-9.62M-8.18M-5.15M-5.22M
Net Interest Income-23.47M-9.41M-5.46M-6.76M-5.58M-699.49K-333K-4.55M-726K-60K130.29K160.5K150.48K36.16K-76.96K-19.24K
Interest Income1.67M985K2.63M1.22M256K00105K34K33.03K59.49K183.22K196.65K59.06K4611.53K
Interest Expense25.14M10.39M8.09M7.98M5.84M699.49K333K4.79M847K108.37K102.2K59.52K55.73K24.57K77K30.77K
Other Income/Expense-31.05M-13.14M361K-12.8M-10.33M5.58M2.85M-4.13M-278K-876K64.61K138.56K142.52K34.5K-99.18K-19.34K
Pretax Income-104.53M-23.96M-68.03M-39.58M-57.03M-47M-33.58M-50.91M-30.34M-26.14M-21.79M-17M-9.48M-8.14M-5.25M-5.25M
Pretax Margin %--80.82%946.19%-109.31%-1194.12%-1775.52%-1444.34%-2003.62%-872.23%-702.39%-401.91%-423.47%-342.04%-510.5%-541.1%-385.69%
Income Tax-24K3K101K120K10K5K9K3K0090.42K079.27K078.89K30.67K
Effective Tax Rate %0.02%-0.01%-0.15%-0.3%-0.02%-0.01%-0.03%-0.01%0%0%-0.41%0%-0.84%0%-1.5%-0.58%
Net Income-104.97M-23.96M-68.13M-39.7M-57.04M-47M-33.59M-50.91M-30.34M-26.14M-21.88M-17M-9.56M-8.14M-5.33M-5.25M
Net Margin %--80.83%947.59%-109.64%-1194.33%-1775.71%-1444.73%-2003.74%-872.23%-702.39%-403.58%-423.47%-344.9%-510.5%-549.23%-385.69%
Net Income Growth %-64.83%-71.62%30.4%-21.36%-39.93%34.03%-67.79%-16.07%-19.48%-28.69%-77.92%-17.33%-52.79%-1.61%-
Net Income (Continuing)-104.51M-23.96M-68.13M-39.7M-57.04M-47M-33.59M-50.91M-30.34M-26.14M-21.88M-17M-9.56M-8.14M-5.33M-5.25M
Discontinued Operations0000000000000000
Minority Interest0000000000000000
EPS (Diluted)--0.50-1.44-1.08-1.64-1.35-1.38-2.35-1.52-1.50-1.43-1.20-0.74-0.76-0.65-3.42
EPS Growth %-65.28%-33.33%34.15%-21.48%2.17%41.28%-54.61%-1.33%-4.9%-19.17%-62.16%2.63%-16.92%80.99%-
EPS (Basic)--0.50-1.44-1.08-1.64-1.35-1.38-2.35-1.52-1.50-1.43-1.20-0.74-0.76-0.65-3.42
Diluted Shares Outstanding48.88M47.82M47.27M36.93M34.85M34.73M24.39M21.63M19.63M17.48M15.28M14.14M12.87M10.75M8.22M1.54M
Basic Shares Outstanding48.88M47.82M47.27M36.76M34.85M34.73M24.39M21.63M19.62M17.43M15.28M14.14M12.87M10.75M8.22M1.54M
Dividend Payout Ratio----------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Milestone-dependent revenue concentration

Lumpy Milestone Revenue Drives Growth

According to the reported income statement, NBTX's quarterly revenue swings from $32.9M in 2023Q4 to negative $16.5M in 2024Q4, indicating that top-line results are driven by irregular partner-linked recognition rather than a steady commercial run-rate.

The quarterly series shows revenue alternating between large recognition events and near-zero or negative periods, which suggests collaboration accounting rather than organic demand is shaping the line. The reported 512% trailing growth therefore reflects a favorable comparison base more than a durable acceleration. Investors should treat the trend as non-representative until revenue stabilizes across several consecutive quarters.

Full Gross Margin Reflects Licensing Economics

Based on reported figures, NBTX's 100% gross margin across all ten quarters, with zero reported COGS, reflects a licensing revenue profile rather than a product-margin structure, leaving the margin signal uninformative about future manufacturing economics.

Because no cost of goods sold is recorded, gross margin carries no information about pricing power or unit economics. The relevant margin signal is the operating line, which has remained negative in nearly every period. Any future physical product would likely introduce variable production costs that the current figures do not yet reflect.

Fixed R&D Base Swamps Revenue Volatility

As reflected in the 2026Q2 figures, NBTX's R&D expense of $11.8M and SG&A of $10.7M exceeded revenue of $5.6M, producing an operating loss of $17.9M and an operating margin of -3.2% on a quarterly basis.

R&D and SG&A have remained in a relatively stable band while revenue has oscillated, so operating results are determined primarily by the timing of top-line recognition. This negative operating leverage suggests that revenue growth alone will not restore profitability unless it scales well beyond the current expense base. Monitoring whether operating losses narrow as revenue normalizes will be the clearest test of structural progress.

Net Losses Exceed Operating Losses

Based on EDBL-style reported figures, NBTX posted a 2026Q2 net loss of $34.7M against an operating loss of $17.9M, a gap that warrants further investigation into non-operating items reported below operating income.

The difference between operating and net loss in several quarters is large enough that non-operating charges, financing costs, or tax effects may be contributing materially. Stock-based compensation of up to $2.4M per quarter also affects reported earnings. The reported EPS trajectory should be read with these items in mind rather than as a clean measure of operating performance.

R&D Dominates a Development-Stage Cost Base

According to reported quarterly figures, NBTX's R&D spending ranged from roughly $8.6M to $22.0M across the ten quarters, making it the dominant cost line and the primary determinant of cash consumption.

R&D consistently exceeds SG&A, consistent with a clinical-stage program carrying multiple trials at once. Expense discipline is hard to judge from the income statement alone because trial timing drives quarterly variation. Investors should watch whether R&D declines as enrollment completes or remains elevated as programs advance.

Revenue Quality Could Prove Non-Recurring

Based on the reported figures, the 512% revenue growth and 100% gross margin could be misread as commercial traction, while the underlying pattern of swinging and negative quarters suggests the revenue base may be non-recurring and partner-dependent.

A bear reading would emphasize that negative quarterly revenue and a persistent operating loss are inconsistent with a scalable commercial business. If milestone recognition slows, the top line could compress sharply against a largely fixed expense base. This analysis is an inference from the reported pattern and does not establish the terms or durability of any specific partner arrangement.

NBTX — Frequently Asked Questions

Quick answers to the most common questions about buying NBTX stock.

What was Nanobiotix S.A.'s (NBTX) revenue in 2025?

For fiscal year 2025, Nanobiotix S.A. (NBTX) reported total revenue of $29.6M. This represents a 2079.1% increase compared to $1.4M in 2011.

Is Nanobiotix S.A. (NBTX) profitable?

Nanobiotix S.A. (NBTX) reported a net loss of $24.0M for the fiscal year ending 2025.

What is Nanobiotix S.A.'s operating profit margin?

Nanobiotix S.A. (NBTX) reported an operating income of $-10.8M, resulting in an operating profit margin of -36.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Nanobiotix S.A.'s gross profit and gross margin?

Nanobiotix S.A. (NBTX) generated $29.6M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.